Parental anxiety in differences of sex development and hypospadias: a psychosocial characterization Authors: Sarah F Schlegel, Jessica Kremen, Alayna Dutcher, Stacey Pereira, Ingrid A Holm, Yee-Ming Chan Published: 2026 ABSTRACT AbstractContextParents of children with differences of sex development (DSD) and hypospadias experience significant psychological distress, but the factors contributing to parental anxiety remain poorly understood.ObjectiveIdentify psychosocial factors associated with anxiety among parents of children with urogenital conditions and compare anxiety levels to parents in other pediatric settings.DesignCross-sectional survey study.SettingPediatric subspecialty clinics at an academic medical center.ParticipantsOne hundred and eight parents of children with urogenital conditions without established genetic diagnoses, compared with 346 parents from BabySeq, a newborn genomic sequencing trial (278 parents of healthy newborns, 68 parents of neonatal intensive care unit [NICU] infants).Main Outcome MeasuresAnxiety symptoms (Generalized Anxiety Disorder 7-item scale [GAD-7]), stigma, and quality of life.ResultsClinically significant anxiety (GAD-7 ≥ 5) was present in 33% of parents of children with urogenital conditions, similar to the rate in parents of NICU infants (34%) and significantly higher than in parents of healthy newborns (21%, P = .03). Forty-one percent reported self-blame for their child's condition; 16% reported blaming their partners. Quality of life decreased with increasing stigma (P = .001), genital atypicality (P = .03), and anxiety scores (P = .04). Backward elimination and Least Absolute Shrinkage and Selection Operator regression with multiple imputation identified 4 key factors predicting increased anxiety: higher intolerance of uncertainty, increased parental health-related stress, lower educational level, and greater emotional stigma. Additional factors included greater genital atypicality, social isolation, and self-blame.ConclusionParents of children with urogenital conditions experience anxiety levels comparable to parents of infants in the NICU, despite their children being medically stable. Uncertainty intolerance and emotional stigma provide targets for clinical screening and early intervention. When a child is diagnosed with a difference of sex development (DSD) or hypospadias, families face a unique set of medical, social, and psychological considerations that can significantly impact family dynamics and well-being. For these families, the experience often extends beyond medical management to encompass profound psychosocial dimensions that may persist throughout the child's development. Differences of sex development are generally defined as congenital conditions in which chromosomal, gonadal, or anatomical sex is atypical (1, 2). This umbrella term encompasses a diverse spectrum of conditions, including sex-chromosome DSD, in which an individual has a sex-chromosome complement other than XX or XY. Some clinicians include diagnoses such as Klinefelter syndrome and Turner syndrome within the DSD umbrella, although many researchers focus specifically on 46,XX patients with virilization and 46,XY patients with undervirilization. Hypospadias, a condition in which the urethral meatus is positioned at a location other than the tip of the glans penis, represents one of the most common congenital anomalies of the male genitourinary system. While DSD that cause atypical genital development are relatively uncommon, occurring in ∼1 out of every 4500 to 5500 births (2), hypospadias affects 1 out of every 150 to 300 male live births (3, 4). This rate exceeds that of Down syndrome in the United States (1 out of 667 live births) (5), making hypospadias one of the most common congenital anomalies (5) and underscoring the substantial public health significance of these urogenital conditions. The combined impact of hypospadias and DSD creates a sizable population of families navigating a similar set of psychosocial challenges. Research has consistently documented the profound psychological burden experienced by the parents of children with urogenital conditions such as hypospadias or DSD. One study found that the parents of children with DSD report posttraumatic stress levels similar to those of parents whose children have survived cancer (6). In addition, being the parent of a child with a urogenital condition such as hypospadias or a DSD can lead to significant anxiety, diminished quality of life, and feelings of stigmatization (7, 8). When the cause of a child's urogenital condition remains undiagnosed, this diagnostic uncertainty may worsen the psychological burden for parents (9). This psychosocial stress not only affects parental well-being but also has the potential to create ripple effects throughout the family system. The possible intergenerational impact is particularly concerning, as children of anxious parents demonstrate a significantly higher risk of developing anxiety disorders themselves (10-12). Despite growing recognition of these psychosocial challenges, significant knowledge gaps persist in understanding the complex interplay of factors contributing to distress among caregivers of children with DSD. Recent guidance from a multi-stakeholder group emphasized the need to develop interventions promoting positive psychosocial adaptation and called for more comprehensive research approaches in this area (13). In particular, international experts have raised concern over the use of single quality-of-life measures in prior studies of caregivers of children with DSD, which may not capture interactions between multiple psychosocial dimensions (2). This cross-sectional study addresses these knowledge gaps through a detailed assessment of psychosocial factors affecting parents of children with urogenital conditions, with particular attention to identifying specific contributors to clinically significant anxiety symptoms. By identifying factors that most strongly associate with parental distress, this research will help clinicians to screen for at-risk families and tailor interventions to support the psychological health of both parents and children facing these challenging diagnoses. Materials and methods Participants This cross-sectional survey study was part of a broader study on the impact of genetic testing. We recruited the parents of patients with urogenital conditions without a known underlying genetic diagnosis from our hospital's urology, endocrinology, and DSD specialty clinics, each of which has social work support available. In total, 108 parents completed baseline surveys (Tables 1 and 2). At the time of the baseline survey, the children ranged in age from 0 to 15 years (median 2 years). All baseline surveys analyzed in this manuscript were completed prior to the return of any genetic testing results, so that responses would not be influenced by knowledge of testing outcomes. The psychosocial impact of receiving genetic results will be presented in a forthcoming manuscript analyzing postresult surveys. Table 1Patient demographicsWorking diagnosis at time of genetic testing n %XY Condition affecting testicular development76 Condition affecting androgen synthesis/action55 Hypospadias with undescended2321 testicles/micropenis Isolated hypospadias6459 Testicular regression syndrome76XX Androgen excess22 External genitalia scorea Median Range Children reared as girls (n = 4)20-5.5 Children reared as boys (n = 98)10.14.75-12 Age (years) 20-15 a The EGS (14) ranges from most typically female (0) to most typically male (12), with an EGS of 6 describing the most atypical appearance. Patient demographics a The EGS (14) ranges from most typically female (0) to most typically male (12), with an EGS of 6 describing the most atypical appearance. Table 2Parent demographics in urogenital and BabySeq cohortsUrogenitalWell babyNICU baby n (%) n (%) n (%)Parent gender Female57 (55)159 (57)34 (50) Male46 (45)119 (43)34 (50)Ethnicity Hispanic10 (10)16 (7)0 (0) Non-Hispanic87 (90)221 (93)66 (100)Race Asian11 (11)35 (14)5 (8) Black/African American6 (6)5 (2)0 (0) White/Caucasian78 (80)206 (81)58 (88) More than one race or other3 (3)8 (3)3 (5)Relationship status Single and never married3 (3)2 (1)0 (0) Single and separated or divorced1 (1)0 (0)0 (0) In a committed relationship101 (96)247 (99)63 (100) Partner is child's biological parent92 (93)240 (98)61 (97)Household income <$20 0005 (5)2 (1)1 (2) $20 000-$49 9998 (8)3 (1)1 (2) $50 000-$99 99915 (15)33 (13)12 (20) $100 000-$199 99942 (42)101 (41)28 (46) $200 000-$499 99927 (27)95 (39)16 (26) ≥$500 0002 (2)11 (4)3 (5)Highest completed education 8th grade or less1 (1)0 (0)0 (0) 9th to 12th grade or GED7 (7)2 (1)1 (2) Vocational school or some college13 (12)15 (6)7 (11) College graduate40 (37)81 (33)21 (33) Graduate or professional school46 (43)151 (61)34 (54)Partner's highest completed education 8th grade or less4 (4)NMNM 9th to 12th grade9 (9)NMNM Vocational school or some college14 (13)NMNM College graduate33 (31)NMNM Graduate or professional school45 (43)NMNM Mean (range) Mean (range) Mean (range) Age (years)36 (25-56)34.5 (22-53)33 (23-49)Not all participants answered all questions, so percentages and totals reflect those who answered the relevant questions.Abbreviations: NICU, neonatal intensive care unit; GED, general educational development; NM, “not measured” in survey. Parent demographics in urogenital and BabySeq cohorts Not all participants answered all questions, so percentages and totals reflect those who answered the relevant questions. Abbreviations: NICU, neonatal intensive care unit; GED, general educational development; NM, “not measured” in survey. The sample size of 108 parents was based on recruitment feasibility within the study period. Patients who already had an established genetic diagnosis were excluded; thus, we excluded patients with sex-chromosome mosaicism, virilizing congenital adrenal hyperplasia, and genetically confirmed diagnoses of androgen insensitivity syndrome. Parents were eligible to participate in surveys if their child was younger than 18 years of age. All parents were literate in English, Spanish, or Arabic (as validated study measures were not available in other languages). This study was approved by the Institutional Review Board at Boston Children’s Hospital (IRB-P00012912). All parents provided written informed consent to participate in the study. The BabySeq Project dataset To compare our baseline findings with another population in a similar region of the country and with similar sociodemographic characteristics, we analyzed data from the BabySeq Project. The BabySeq Project is a randomized clinical trial exploring the medical, behavioral, and economic impact of using whole-exome sequencing as an adjunct to traditional newborn screening in healthy newborns and infants in the neonatal intensive care unit (NICU) (15). Infants were eligible to participate in the study if they were younger than 43 days, had not previously undergone exome sequencing, were born of a single-gestation pregnancy, and were either admitted to the Brigham and Women's Hospital Well Newborn Nursery (the “well-baby cohort”) or to an intensive care unit at Brigham and Women's Hospital or Boston Children's Hospital (the “NICU baby cohort”). Families were excluded if the parents were non-English speaking, younger than 18 years of age, or had impaired decisional capacity, or if clinical considerations precluded drawing 1 mL of blood from the infant. Because the Generalized Anxiety Disorder 7-item scale (GAD-7) was not administered at baseline in the BabySeq study, our anxiety comparisons used the BabySeq 3-month postdisclosure survey. Baseline surveys were completed within 2 weeks of enrollment and thus served as a proxy for enrollment date. The 3-month survey was completed a median of 225 days after baseline (IQR 187-264), when infants were a median of 7.8 months old (range 4.6-14.1); all had been discharged by this time. The BabySeq Project was approved by the Boston Children’s Hospital and Massachusetts General Brigham institutional review boards, as previously described (15, 16). Survey measures The surveys analyzed in this study included questions that spanned multiple different psychosocial domains (Table 3). For the parents of children with urogenital conditions (“urogenital cohort”), we conducted extensive psychosocial assessments using all domains listed in Table 3. For comparison with the BabySeq Project, we analyzed a subset of the measures collected in both studies: GAD-7 anxiety symptom scores, Patient Health Questionnaire-9 (PHQ-9) depression symptom scores, and demographic variables (gender, race, ethnicity, age, and household income). Table 3Psychosocial domains measured in baseline surveysVariable domainsSurvey tools Participant characteristics SociodemographicsSociodemographic questionnaire derived from the NHANES demographic and background questionnaire, as well as NIH standards for reporting race/ethnicity Genetic perceptionSurvey instruments developed in collaboration with BabySeq investigators to describe previous experiences with genetic testing (15, 16) SupportsInstrument derived from Pew Research Center to assess religion and spirituality (17) and The Multidimensional Scale of Perceived Social Support (18, 19) ConfidenceThe Intolerance of Uncertainty scale (20) Personal and family historyTools used to gather health history derived from the Short-Form Health Survey (SF-12) (21), the Pregnancy Risk Assessment Monitoring System (22), and the BabySeq Project (15, 16); questions about fertility and DSD diagnosis developed by the Boston Children's Division of Endocrinology's Disorders of Sex Development Research Conference Psychological wellness Personal distress (depression and anxiety)The PHQ-9 scale (23) and the GAD-7 scale (24) Parent–child relationship and child-centered stressThe Parenting Stress Index version 4 (25, 26) Perceptions of childThe Child Health Worry Scale derived from the Vulnerable Baby Scale (27) Perceived self-blame, partner blameInstrument developed in collaboration with BabySeq investigators as a measure of blame regarding child's diagnosis (15, 16) DSD-specific measures DSD-associated stigmaThe DSD-Associated Stigma measure (8) DSD-related quality of lifeThe DSD Health-Related Quality of Life instrument (28)Abbreviations: DSD, differences of sex development; NIH, National Institutes of Health. Psychosocial domains measured in baseline surveys Abbreviations: DSD, differences of sex development; NIH, National Institutes of Health. The “participant characteristics” category of questions included sociodemographics such as race, ethnicity, relationship status, and household income; perceptions of genetic testing based on previous experiences (developed in collaboration with BabySeq investigators) (15, 16); an instrument derived from Pew Research Center to assess religion and spirituality (17); the Multidimensional Scale of Perceived Social Support to measure the parent's social connectedness (18, 19); measures of attitudes and confidence such as the Intolerance of Uncertainty scale (to assess parents' ability to cope with uncertainty) (20); and specific questions about the parent's medical and family history (including items derived from the 12-Item Short-Form Health Survey (21) and the Pregnancy Risk Assessment Monitoring System (22)). Multiple validated tools were included to measure the psychological wellness of parents and family units, such as the PHQ-9 scale to measure depressive symptoms (23), the GAD-7 scale to measure anxiety symptoms (24), the Parenting Stress Index to measure stresses in the parent–child relationship (25, 26), and the Child Health Worry Scale to measure the parent's assessment of the child's vulnerability (27). The surveys also included questions specific to patients undergoing genetic testing, such as questions developed in collaboration with BabySeq investigators about self-blame and partner blame regarding the child's diagnosis. Questions specific to patients with urogenital conditions included the DSD-associated stigma measure, a validated instrument used to assess stigma in the families of children with DSD (8). Finally, we included the DSD Health-Related Quality of Life (QOL) instrument, a validated tool that includes questions about topics such as medical decision-making, the child's role in family activities, gender concerns, social functioning, concerns about the future, and experiences with the healthcare system (28). The surveys were administered online using REDCap (29), with paper versions offered to those unable to complete electronic forms. Multiple imputation To address missing survey data (6.2% of summary-score data), we performed multiple imputation using the Multiple Imputation by Chained Equations (MICE) package in R. This package acknowledges the uncertainty of the missing values by creating multiple plausible estimates for the missing values rather than using listwise deletion, which has the potential to introduce bias (30). Following recommended guidelines that the number of imputations should be greater than the percentage of missing data (30, 31), we conservatively performed 20 iterations of imputation. Measurement of genital typicality To quantify the patients' degree of genital atypicality, we reviewed medical records and used findings from physical examinations documented prior to any urogenital surgical interventions to determine the External Genitalia Score (EGS), a standardized description of external genitalia for preterm and term babies up to 24 months of age (14). The EGS gives points for different physical features, such as length of the genital tubercle, location of the urethral meatus, degree of fusion of the labioscrotal structures, and ability to palpate the gonads. Possible scores range from typical female appearance (0) to typical male appearance (12), with an EGS of 6 describing the most atypical appearance (14). In this study, if a range of possible scores was suggested by the exam documented in the chart, the final score selected was the average of the highest and lowest possible scores consistent with the exam. Based on the hypothesis that psychosocial stressors would be associated with degree of atypicality rather than whether the child's genitalia appeared more typically male or typically female, we also calculated a “genital typicality score” by taking the absolute value of the difference between the child's EGS and 6 (the most atypical, intermediate score). Statistical analyses Mixed-effects bivariate modeling To understand the psychosocial factors that contribute to the quality of life of the families of children with urogenital conditions, we performed association studies between QOL and other psychosocial tools in the survey. To account for the possibility of a correlation between the responses for the mother and father of the same child, we created mixed-effects models for this analysis. This technique accounts for potential correlations between parent responses by incorporating a random-effect value for each parent pair. We also used linear and logistic mixed-effects models with the GAD-7 score as the outcome to test our hypothesis that the degree of anxious symptoms (as measured by GAD-7 scores) in the parents of children with urogenital conditions was greater than that experienced by the parents of children in the BabySeq healthy newborn group but similar to that experienced by the parents of children in the BabySeq NICU group. We added additional psychosocial variables to the mixed-effects models to control for possible confounders of group differences in anxiety scores, such as the parent's gender, self-reported ethnicity and race, age, and household income. Clinically significant anxiety symptoms were defined as GAD-7 scores ≥5, consistent with established clinical cutoffs (24). Parents in the BabySeq comparison cohorts had been randomized to receive newborn genomic sequencing (experimental arm) or standard newborn screening with a family history report (control arm), whereas no child in the urogenital cohort had undergone genetic testing at the time of the survey. To assess whether this difference in genetic-testing exposure contributed to the observed differences in anxiety between cohorts, we conducted a sensitivity analysis in which the BabySeq randomization arm was added as a covariate to the models comparing anxiety symptoms across cohorts. The randomization arm was obtained from BabySeq study records and was treated as a fully observed variable (identical across all imputations and contributing no imputation uncertainty), with all urogenital participants assigned to the control category to reflect their untested status at the time of the survey. We repeated both the continuous GAD-7 comparison (linear mixed-effects model) and the presence of clinically significant anxiety comparison (logistic mixed-effects model), each with and without adjustment for the demographic covariates used in the primary analysis (parent gender, race, ethnicity, age, and household income). Multivariate modeling of GAD-7 To elucidate the major psychosocial features related to the high levels of anxious symptoms in the parents of children with urogenital conditions, we performed multivariate modeling of GAD-7 scores. To determine which variables should be included in the multivariate model, we first examined relationships between variables using correlation tables, using Pearson correlation coefficients for variables with minimal correlation between parent pairs and using the square root of the R2 value of linear mixed-effects models for variables demonstrating interparental correlation. Variables with correlation coefficients >0.7 or <−0.7 were considered for exclusion to prevent collinearity. Only one such pair was identified (r = 0.87); the variables had nearly identical values for all participants, as both described a similar phenotype (“presence of hypospadias with urethral opening within the scrotum”), and we retained only the variable with the stronger association with GAD-7. For measures with subdomains, we excluded aggregate psychosocial scores in favor of including their subscores as more specific predictors. We also excluded variables for which >95% of participants gave the same response (ie, variables that did not meaningfully differentiate between participants). Finally, because PHQ-9 (for depressive symptoms) is known to be closely associated with GAD-7 and we were concerned that its inclusion would mask the contributions of other variables to the GAD-7 score, we also excluded PHQ-9 and other depression scores in our main analysis models. To build the multivariate models, we employed the Least Absolute Shrinkage and Selection Operator (LASSO) technique, which reduces the risk of overfitting through cross-validation and coefficient shrinkage. This approach is superior to many other methods used for multivariate regression modeling due to this reduced risk of overfitting, increased model interpretability, and improved ability to accurately model the same outcome in other samples drawn from the same population (32). To address missing data, we applied the LASSO technique to our multiply imputed dataset using the “separate approach” described by a recent publication (31), which constructs a different model for the dataset arising from each imputation iteration. We selected this method due to its more parsimonious selection process and increased predictive performance. Because there was minimal correlation between GAD-7 scores within parent pairs (r = 0.08), we did not include random effects for parent clustering, similar to the approach used in the BabySeq Project when there was no significant within-family clustering in the outcome measure (16). We implemented 10-fold cross-validation, with lambda values derived by averaging the optimal values across all 20 imputations. The variable coefficient outputs for each imputed dataset were then averaged (if a particular variable was not selected in one of the imputations, then that variable was considered to have a coefficient of zero). We constructed 2 models: LASSO Model 1 included all variables except those explicitly excluded above. Following established practice for data analysis when the number of predictors exceeds sample size, we also constructed LASSO Model 2, for which we first identified variables that were associated with GAD-7 in univariate analysis with P ≤ .15 before applying LASSO (33). To compare the relative contributions of different variables, normalized predictor variable coefficients were calculated by taking the absolute value of the mean of all normalized predictor coefficients from iterations where each predictor was included in the model. Finally, we cross-checked our models by repeating the model-building on the multiply imputed dataset with the backward elimination selection technique (a method that removes variables one by one based on their pooled P-values in the presence of all other variables) (34). Results Participant demographics Our study included 108 parents of children with urogenital conditions, with 55% mothers and 45% fathers (median age 36 years, range 25-56). Most participants (80%) described their race as white, with a smaller proportion describing themselves as Asian (11%), Black or African American (6%), or more than one race (3%). Twenty-nine percent of parents had a household income of at least $200 000/year, and 13% reported an income of <$50 000/year. These 108 parents represented 68 children, of whom 40 had both parents complete the survey and 28 had one parent respond. At the time of the baseline survey, the age of the patients in this study ranged from 0 to 15 years, with a median age of 2 years. The majority of children at some point underwent a surgery that altered the appearance of the genitourinary area, and 74 of the 108 parental surveys (69%) were completed after the child had undergone such a surgery. The cohort thus includes both pre- and postsurgical survey responses. The working diagnoses of the patients at the time of study enrollment included isolated hypospadias (59%), hypospadias with undescended testicles and/or micropenis (21%), conditions affecting testicular development (6%), conditions affecting androgen synthesis/action (5%), testicular regression syndrome (6%), and androgen excess (2%). Complete demographics for patients and parents are presented in Tables 1 and 2, respectively. When comparing the urogenital cohort with the BabySeq cohorts, we found that a greater percentage of the urogenital cohort had household income <$50 000 per year compared with the parents of healthy infants in the newborn nursery (“well-baby cohort,” n = 278) and the parents of ill newborns in the NICU (“NICU baby cohort,” n = 68) (13%; 2%; 3%), and a lower percentage had graduated from college compared with the BabySeq well and NICU cohorts (80%; 93%; 87%). Although the BabySeq NICU enrollment criteria did not preselect infants by suspicion for a genetic disorder (35), the resulting NICU baby cohort (n = 41) was weighted toward infants with clinically significant illness (Table S1) (36). Congenital heart defects (n = 10) and multiple congenital anomalies (n = 9) accounted for 46% of this cohort, 34% of infants had conditions typically requiring surgery, and 49% required continuous positive airway pressure (CPAP) or higher respiratory support vs 1.1% of well-baby infants. The NICU baby cohort had a median NICU stay of 22 days (compared with 0 days for well-baby cohort), a median hospital stay of 27 days (compared with 4 days for well-baby cohort), and a median of 3 specialty consultations (compared with 0 for well-baby cohort). Median gestational age in the NICU baby cohort was 38.1 weeks, with 29% born preterm (37) (compared with 4% of the well-baby cohort). Parental self-blame and partner blame Because previous studies identified self-blame as a significant cause of stress in the parents of children with genetic conditions (38), we examined participants' experiences of blame. We found that 41% of participants described blaming themselves at least “a little” for passing harmful genes to their children (Fig. 1), similar to the 42% frequency of self-blame that has been reported by parents of children with cystic fibrosis (38). In addition, 16% described blaming their partners at least “a little” (Fig. 1). Distribution of responses to the survey questions, “How much do you blame yourself/your partner for passing potentially harmful genes on to your child?” among 108 parents of children with urogenital conditions. DSD-related quality of life To understand the psychosocial factors that contribute to diminished quality of life experienced by some families of children with urogenital conditions, we performed association studies between QOL and other psychosocial tools in the survey using linear mixed-effects models. With this modeling technique, we found that QOL decreased with increasing DSD-associated stigma (β = −10.61 [95% CI: −16.42 to −4.80]; P = .001), increasing genital atypicality (14) (β = −2.93 [95% CI: −5.63 to −0.23]; P = .03; Fig. 2), and increasing anxiety scores (β = −0.60 [95% CI: −1.16 to −0.04]; P = .04; Fig. 3). To further explore the presence of anxious symptoms in our population, given their association with QOL and their previously identified association with having a child with a urogenital condition (7), we quantified the prevalence of anxious symptoms in our cohort. We found that 33% of respondents had GAD-7 scores demonstrating anxious symptoms in the clinically significant range, a greater proportion than the 16% frequency reported in the general population (39). DSD-Related Quality of Life (28) decreases with increasing genital atypicality as measured by the EGS (14). The EGS ranges from most typically female (0) to most typically male (12), with an EGS of 6 describing the most atypical appearance. For this analysis, linear mixed-effects modeling was performed with multiply imputed data. The data points in the graph represent only the data collected in the study and do not include the imputed values. DSD-Related Quality of Life (28) decreases with increasing anxious symptoms as measured by the GAD-7 score (24) (P = .04). For this analysis, linear mixed-effects modeling was performed with multiply imputed data. The data points in the graph represent only the data collected in the study and do not include the imputed values. Comparisons with the BabySeq Project The urogenital cohort had higher GAD-7 scores than parents of healthy newborns (mean difference 1.14 [95% CI: 0.31-1.97]; P = .007), even after controlling for parents' gender, race, ethnicity, age, and household income (adjusted 95% CI: 0.25-2.03; P = .01), but similar GAD-7 scores to parents of children in the NICU (mean difference 0.07 [95% CI: −1.06 to 1.20]; P = .9). Anxiety symptom scores in the clinically significant range (GAD-7 ≥ 5) were present in a greater proportion of the parents of children with urogenital conditions (33%) than the BabySeq healthy newborn cohort (21%; odds ratio [OR] 1.77 [95% CI: 1.04-3.01]; P = .03), but at a similar proportion to the BabySeq NICU cohort (34%; OR 0.94 [95% CI: 0.47-1.85]; P = .8), despite the fact that the children with urogenital conditions were clinically stable at home rather than in a critical-care unit (Fig. 4). After controlling for parents' gender, race, ethnicity, age, and household income, the difference in the frequency of clinically significant anxiety between the urogenital and well-baby groups remained borderline significant (adjusted OR 1.78 [95% CI: 1.00-3.17]; P = .051). Anxious symptoms in the clinically significant range (GAD-7 score ≥5) (24) were present in a greater proportion of the parents of children with urogenital conditions (33%) than in the parents of children in the BabySeq healthy newborn group (21%). A comparable proportion of the parents of children in the BabySeq NICU group had clinically significant anxious symptoms (34%). Standard error bars are shown. Logistic mixed-effects modeling was used for the analysis. The BabySeq Project involved randomization to either genomics-enhanced newborn screening or standard newborn screening. To assess whether this randomization influenced anxiety scores, we repeated the GAD-7 comparisons with the randomization arm included as a covariate, with and without adjustment for demographic variables. We did not observe any attenuation of the difference between the urogenital and well-baby cohorts in any model (Tables S2 and S3) (36). There was no significant difference in PHQ-9 scores for depressive symptoms between the urogenital cohort and parents of healthy newborns (mean difference 0.53 [95% CI: −0.29 to 1.34]; P = .21) or parents of children in the NICU (mean difference −0.20 [95% CI: −1.29 to 0.89]; P = .72). Similarly, differences in the frequencies of clinically significant depressive symptoms (PHQ-9 ≥ 10) between the urogenital cohort and parents of healthy newborns did not reach statistical significance (urogenital 6.0% vs healthy 3.0%; OR 2.41 [95% CI: 0.70-8.32]; P = .16) or parents of children in the NICU (NICU 4.5%; OR 1.54 [95% CI: 0.24-9.94]; P = .65), and these differences remained nonsignificant when controlling for demographic factors. Multivariate modeling of GAD-7 scores To elucidate the major psychosocial features related to the high levels of anxiety symptoms in the parents of children with urogenital conditions, we used a systematic modeling approach. Based on findings in other populations, we hypothesized that the high levels of anxiety symptoms observed among the parents of children with urogenital conditions would be most closely associated with other psychosocial issues such as increased depressive symptoms (40), other life factors such as poorer caregiver health (41, 42), and socioeconomic factors such as lower income (41). To identify factors with the most robust associations with parental anxiety, we employed multiple complementary analytical approaches: backward elimination (which systematically removes less important variables) and LASSO regression applied to multiply imputed datasets (which created 20 separate models to account for missing data uncertainty, ensuring that our findings are not dependent on assumptions about missing values). Across all modeling approaches, 4 factors were consistently associated with increased anxiety: (1) higher intolerance of uncertainty, (2) increased parental health-related stress, (3) lower parental educational level, and (4) greater parental emotional stigma related to the condition (Fig. 5). These 4 key factors all had mean normalized coefficients that were among the 11 largest in LASSO Model 1 (built with all variables) and among the 8 largest in LASSO Model 2 (built with variables that were associated with GAD-7 in univariate analysis). Variables selected by different methods of multivariate modeling. LASSO 1 included as inputs all survey variables from the parents of children with urogenital conditions; LASSO 2 included only variables associated with GAD-7 with P ≤ .15. Variables shown in LASSO results were selected in at least 50% of all imputations from the multiply imputed datasets. Percentages describe the proportion of the 20 total LASSO analyses (one for each imputation) that identified the given variable as being associated with the parent's GAD-7 score; the first percentage describes the results of LASSO 1, and the second percentage describes the results of LASSO 2. All variables selected by the backward elimination pooled P-value method were selected by both LASSO models. HS, high school; LASSO, least absolute shrinkage and selection operator; QOL, DSD-Related Quality of Life. Other factors that frequently emerged in LASSO Model 1 and LASSO Model 2 included increased genital atypicality, loss of personal identity beyond parenting, poor parental social functioning, increased difficulty discussing the child's condition with others, greater self-blame, and increased concerns about future stigma for the child, while frequent religious service attendance emerged as potentially protective. Because PHQ-9 scores (for depressive symptoms) correlate strongly with GAD-7 scores (for anxiety symptoms), we omitted PHQ-9 from our initial analyses. We then repeated our analyses including PHQ-9 to test the robustness of our findings. All 4 key factors remained significantly correlated with anxiety symptoms in these models, confirming their independent importance (Fig. S1) (36). Discussion In this study, we characterized experiences of stigma, quality of life, and self-blame among parents of children with congenital urogenital conditions (DSD and hypospadias) and identified key psychosocial factors associated with parents' anxiety symptoms. Our findings highlight several important patterns that carry direct clinical implications for supporting these families. First, we found high rates of parental self-blame. The prevalence of self-blame is similar to reports of self-blame among parents of children with cystic fibrosis (38) and provides important insight into a potential driver of psychological distress in these families. Our quality-of-life analyses revealed that increased experiences of stigma and greater genital atypicality were both associated with decreased quality of life among parents. While causality cannot be established in this cross-sectional study, these relationships highlight the impact of both social and physical factors in parental adjustment to these conditions. Strikingly, we found that parental anxiety in this population is comparable to that experienced by parents of children who had been in the NICU. The elevated anxiety we observed in the urogenital cohort relative to parents of healthy newborns does not appear to be driven by differences in genetic-testing exposure between the cohorts, as it was not attenuated after adjusting for BabySeq randomization arm. This is consistent with the primary BabySeq psychosocial analysis, which found no sustained differences in anxiety between the sequencing and control arms over time (16). As detailed above, the BabySeq NICU cohort comprised genuinely ill infants rather than predominantly stable infants admitted for prematurity; thus, the urogenital cohort's anxiety levels approached those of parents who had faced serious neonatal illness. The similarity in anxiety levels indicates that the emotional impact of these diagnoses should not be underestimated and that psychological support should be as readily available in outpatient urogenital care as it is in acute critical-care settings. Through multivariate modeling, we identified 4 key factors associated with increased anxiety in this population: increased parental health-related stress, lower parental educational level, greater emotional stigma related to the condition, and higher intolerance of uncertainty. Some of these factors—particularly poor parental health and lower educational level—likely contribute to anxiety in many populations beyond parents of children with urogenital conditions. However, the emotional stigma component appears uniquely relevant to this specific population, underscoring the distinct psychological burden these parents face. Our finding that emotional stigma strongly correlates with anxiety confirms the well-documented psychosocial impact of perceived societal attitudes toward urogenital conditions, particularly amid increased public discourse around gender and biological sex. This finding adds to the established evidence that among the parents of children with DSD, stigma significantly contributes to the psychological burden for families (43-45), similar to patterns observed in other stigmatized conditions such as HIV and epilepsy (46, 47). Uncertainty intolerance showed a remarkably strong association with anxiety in our population, remaining significant across all our analytical approaches—even when we controlled for depression symptoms (PHQ-9). The prominence of uncertainty intolerance in our model suggests that parents with higher anxiety may find it particularly challenging to cope with the unknowns regarding their child's diagnostic workup, treatment outcomes, and future psychosocial adjustment to the urogenital condition. This finding is consistent with prior reports that illness uncertainty among the parents of children with DSD is comparable to that of parents of children with other chronic illnesses such as type 1 diabetes mellitus (7), and previous research has found that illness uncertainty in such chronic conditions is a robust predictor of parental psychological distress over time (48). Social identity concerns also emerged as a prominent theme in our models. Notably, the PSI4 subscale “increased limitation of parent's personal identity imposed by parenthood” appeared frequently in both LASSO models. This experience—where parents feel they must devote most of their energy and identity to parenting at the expense of their individual identity—has been well-documented among parents of children with various chronic conditions (47, 49). The prominence of the PSI4 subscale “parent perception that child is demanding” in our models further reflects the heightened caregiving burden associated with managing a child's chronic condition. Beyond individual parenting experiences, broader concerns about social functioning also emerged in our analyses. The “parental sense of isolation” subscale consistently emerged alongside other social factors such as “poor QOL due to parental social functioning” and difficulties discussing the child's condition with others. These findings align with research documenting social isolation among parents of children with other chronic conditions, including disabilities (50), inflammatory bowel disease (51), attention-deficit/hyperactivity disorder (ADHD) (52), and autism spectrum disorder (53). The potentially protective effect of religious service attendance against anxiety identified in our models further suggests the importance of community integration. Clinical recommendations Our findings suggest several important clinical practice changes to better support parents of children with urogenital conditions. First, we recommend systematic screening for potentially modifiable factors associated with anxiety, particularly intolerance of uncertainty and emotional stigma (see intervention approaches discussed below). This targeted screening would help identify parents who may benefit from early psychosocial intervention. Screening for parental health concerns is also important, as our findings emphasize that a child's urogenital condition represents only one aspect of a family's overall experience, and other stressors may compound psychological impact. Parents who screen positively for these risk factors should undergo formal anxiety assessment and may benefit from proactive referral to appropriate mental health services. Given the high prevalence of self-blame in this population, clinicians should address this topic during clinical visits. This discussion should normalize these feelings while providing accurate information about inheritance patterns. Clinicians should also provide guidance on approaches to navigating social situations and sharing information about the child's condition, addressing the social isolation many parents experience. Our finding that 33% of parents experience clinically significant anxiety—a rate comparable to parents of children who had been in the NICU—reinforces existing DSD consensus recommendations that psychosocial and mental health support be integrated into the care of affected families (1, 13) and provides further justification for embedding mental health services within urogenital specialty care settings. These services could include specialized support groups focused on strategies for coping with uncertainty and managing stigma. Research in other populations offers promising approaches: studies among oncology patients and caregivers have demonstrated success with home-based interventions that provide support around illness uncertainty by teaching skills to obtain information, increase one's assertiveness, and learn to live with uncertainty (54-56). To address stigma, evidence in conditions such as HIV/AIDS, mental illness, and epilepsy supports multiple approaches, including individual counseling/cognitive behavioral therapy, advocacy and support groups, community-based programs, and broader community education initiatives (57, 58). Several existing interventions to improve parental anxiety also show promise for adaptation to this population. For example, an online mindful parenting intervention demonstrated medium effect sizes for improving symptoms of depression and anxiety, with additional benefits for parenting discipline, self-compassion, and child emotional reactivity. This intervention also showed specific improvements in parental role restriction—a factor prominently identified in our models (59). Finally, the protective effect of religious service attendance suggests the value of community integration. Clinicians should inquire about and encourage connection to supportive community resources as potential buffers against isolation and anxiety. This aligns with our finding that social factors play a crucial role in parental well-being, highlighting the importance of addressing not only medical aspects of care but also the broader social context in which families navigate these conditions. Study strengths Our study has several notable strengths. First, the extensive nature of our psychosocial assessment, incorporating multiple validated instruments across various domains, allowed us to capture a detailed picture of parental experiences. The inclusion of both mothers and fathers provides valuable insight into the experiences of both parents, addressing a gap in previous literature that often focused primarily on maternal perspectives. The comparison with BabySeq cohorts represents another key strength, allowing us to contextualize our findings within both healthy and acute-care populations. This comparison provides important insights into the relative psychological impact of having a child with a urogenital condition compared with other medical scenarios. Our analytical approach also represents a methodological strength. The use of multiple imputation and state-of-the-art modeling techniques, including LASSO variable selection, enhanced the robustness of our findings. Additionally, the consistency of our findings across different analytical approaches supports their validity. Lastly, our study's focus on parents of children without established genetic diagnoses addresses an important knowledge gap, as this population may face unique uncertainties and challenges compared to families with confirmed genetic conditions. Study limitations Several limitations should be considered when interpreting our results. The diversity of diagnoses in our study population limited our ability to identify diagnosis-specific patterns, allowing only for analysis of patterns applicable across multiple urogenital conditions. Our sample also demonstrated limited demographic diversity, with most participants identifying as White, high income, and highly educated. This limits our ability to determine the impact of sociodemographic factors (eg, educational attainment, income, and racial/ethnic background) on psychosocial outcomes and constrains the generalizability of our findings to more diverse populations. The study design was also subject to potential recall bias in retrospective questions and responder bias. Missing data is a limitation of any survey-based methodology, although we attempted to mitigate the effects of missing data through use of multiple imputation. The urogenital and BabySeq cohorts differed in patient age; the median age of BabySeq participants was 7.8 months at the survey (range 4.6-14.1 months), while the median age of children in the urogenital cohort was 2 years (range 0-15 years). Our comparison therefore contextualizes parental anxiety across clinically distinct situations rather than serving as an age-matched analysis. The presence of elevated anxiety well beyond the acute neonatal period in both cohorts underscores that these families' psychosocial burden warrants attention beyond the initial diagnostic period. Future directions Several research directions emerge from this work. One notable stressor for these families is uncertainty regarding the underlying cause of the condition. Genetic testing plays an important role in the evaluation of urogenital conditions and has the potential to reduce this uncertainty, but research on its impact is mixed: some studies associate receiving genetic results with increased parental anxiety (60-62), while others report decreased anxiety after receiving positive results (15, 16) and relief from worry after receiving exome-sequencing results (63). Understanding the psychological consequences of genetic testing is crucial for providing sensitive care, and comparative analysis of anxiety correlates between our cohort and the BabySeq cohorts may also help to distinguish associations specific to urogenital conditions from those common to anxious parents more broadly. Future work should also examine how anxiety and support needs evolve as children age and whether interventions targeting social isolation and stigma are beneficial. Particularly promising are narrative medicine and reflective writing interventions, which have shown benefits for psychosocial stress in caregivers (64-66) and in individuals experiencing high levels of shame or stigma (67, 68). Summary and conclusions Our findings offer valuable insight into the psychological experiences of parents of children with urogenital conditions. The discovery that these parents experience anxiety levels comparable to parents of children who had been in intensive care underscores the profound psychological impact of these conditions. The 4 key anxiety-related factors we identified—uncertainty intolerance, parental health challenges, lower educational attainment, and emotional stigma—provide a framework for understanding parental distress, and their interaction with social isolation illuminates the compounded challenges many families face. The potential protective effect of community engagement offers a promising direction for future exploration of resilience factors. By documenting both challenges and protective factors, this work adds to a growing body of urogenital care research and supports a more comprehensive, integrated approach to care, addressing both physical and psychosocial dimensions, that may ultimately enhance both parental well-being and child outcomes.